JP2013503862A - 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 - Google Patents

酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 Download PDF

Info

Publication number
JP2013503862A
JP2013503862A JP2012527871A JP2012527871A JP2013503862A JP 2013503862 A JP2013503862 A JP 2013503862A JP 2012527871 A JP2012527871 A JP 2012527871A JP 2012527871 A JP2012527871 A JP 2012527871A JP 2013503862 A JP2013503862 A JP 2013503862A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
aryl
hydrogen
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012527871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503862A5 (cg-RX-API-DMAC7.html
Inventor
イー． ジェンキンス，トーマス
オー． フスフェルド，クレイグ
ディー． セローギー，ジュリー
ダブリュー． レイ，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signature Therapeutics Inc
Original Assignee
Signature Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature Therapeutics Inc filed Critical Signature Therapeutics Inc
Publication of JP2013503862A publication Critical patent/JP2013503862A/ja
Publication of JP2013503862A5 publication Critical patent/JP2013503862A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
JP2012527871A 2009-09-08 2010-04-21 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 Pending JP2013503862A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24061109P 2009-09-08 2009-09-08
US61/240,611 2009-09-08
US28814809P 2009-12-18 2009-12-18
US61/288,148 2009-12-18
PCT/US2010/031956 WO2011031350A1 (en) 2009-09-08 2010-04-21 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015190867A Division JP2016041698A (ja) 2009-09-08 2015-09-29 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物

Publications (2)

Publication Number Publication Date
JP2013503862A true JP2013503862A (ja) 2013-02-04
JP2013503862A5 JP2013503862A5 (cg-RX-API-DMAC7.html) 2013-06-06

Family

ID=43732738

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012527871A Pending JP2013503862A (ja) 2009-09-08 2010-04-21 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
JP2015190867A Pending JP2016041698A (ja) 2009-09-08 2015-09-29 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
JP2018100108A Active JP6778234B2 (ja) 2009-09-08 2018-05-25 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015190867A Pending JP2016041698A (ja) 2009-09-08 2015-09-29 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
JP2018100108A Active JP6778234B2 (ja) 2009-09-08 2018-05-25 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物

Country Status (13)

Country Link
US (2) US9493477B2 (cg-RX-API-DMAC7.html)
EP (1) EP2475429B1 (cg-RX-API-DMAC7.html)
JP (3) JP2013503862A (cg-RX-API-DMAC7.html)
CN (1) CN102695545B (cg-RX-API-DMAC7.html)
AU (1) AU2010293028B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012005124B1 (cg-RX-API-DMAC7.html)
CA (1) CA2773340C (cg-RX-API-DMAC7.html)
IL (1) IL218498A (cg-RX-API-DMAC7.html)
MX (1) MX348262B (cg-RX-API-DMAC7.html)
PH (1) PH12012500485A1 (cg-RX-API-DMAC7.html)
RU (1) RU2600736C2 (cg-RX-API-DMAC7.html)
SG (1) SG179026A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011031350A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502972A (ja) * 2011-01-11 2014-02-06 シグネーチャー セラピューティクス，インク． 酵素切断可能なオキシコドンプロドラッグを含んでなる組成物
JP2021504351A (ja) * 2017-11-24 2021-02-15 ビョンディス・ビー．ブイ．Ｂｙｏｎｄｉｓ Ｂ．Ｖ． リンカー薬物化合物ｖｃ−ｓｅｃｏ−ＤＵＢＡ製造のための改善された方法
JP2021532183A (ja) * 2018-07-27 2021-11-25 コンセントリック アナルジェジクス，インク． フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348262B (es) * 2009-09-08 2017-06-05 Signature Therapeutics Inc * Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
BR112012026768A2 (pt) * 2010-04-21 2015-09-29 Signature Therapeutics Inc composições compreendendo pró-farmacos de opioides cliváveis de modo enzimático e seus inibidores.
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
TWI483748B (zh) 2010-05-10 2015-05-11 Euro Celtique Sa 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
CA2827662C (en) 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
EP2760844B1 (fr) * 2011-09-29 2018-11-21 Ecole Normale Superieure De Lyon Substrat de peptidase fluorogene
HK1197191A1 (en) 2011-10-26 2015-01-09 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
BR112016009749A8 (pt) 2013-11-13 2018-01-30 Euro Celtique Sa hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
CA2932477C (en) 2013-12-06 2023-10-10 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US9682076B2 (en) 2014-12-02 2017-06-20 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
CN113624665A (zh) * 2021-07-30 2021-11-09 中国药科大学 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176644A1 (en) * 2003-09-30 2005-08-11 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
JP2007507520A (ja) * 2003-09-30 2007-03-29 ニュー リバー ファーマシューティカルズ インコーポレイテッド 過剰摂取又は乱用を防止するための薬学組成物
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
WO2007120648A2 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
WO2007140272A2 (en) * 2006-05-26 2007-12-06 Pharmacofore, Inc. Controlled release of phenolic opioids
US20090137618A1 (en) * 2007-11-26 2009-05-28 Jenkins Thomas E Pro-drugs for controlled release of biologically active compounds
JP2012509846A (ja) * 2008-10-17 2012-04-26 ファーマコフォア，インク． フェノール性オピオイドの放出が減弱された医薬組成物
JP2013525348A (ja) * 2010-04-21 2013-06-20 シグネーチャー セラピューティクス，インク． 酵素切断可能なオピオイドプロドラッグとそのインヒビターとを含んでなる組成物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
CA2032420A1 (en) 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
WO1997037969A1 (en) 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
EP1151090B1 (en) 1998-12-15 2009-09-02 Applera Corporation Multiple enzyme assays
JP2002537243A (ja) * 1999-02-18 2002-11-05 スーパージェン インコーポレイテッド ホスホコリン結合プロドラッグ誘導体
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
DE60239679D1 (de) * 2001-06-11 2011-05-19 Medarex Inc Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
SI1644019T2 (en) 2003-05-29 2018-04-30 Shire Llc AMPHETAMINE COMPOUNDS COMPOUNDS TO ABUSE
AU2004286239A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
FR2881363B1 (fr) * 2005-02-02 2008-03-14 Commissariat Energie Atomique Dispositif d'analyses biologiques avec detecteur integre
EP1928881A2 (en) 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
WO2007025249A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2008101202A1 (en) 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
US20110105381A2 (en) 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
WO2009080030A1 (en) 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
WO2009092071A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
EP2252150B1 (en) * 2008-02-14 2018-04-11 Alkermes, Inc. Selective opioid compounds
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
CN102573845A (zh) 2009-04-02 2012-07-11 夏尔有限责任公司 新的阿片样物质的二羧酸连接的氨基酸和肽前药及其用途
US20110015182A1 (en) 2009-07-17 2011-01-20 Richard Franklin Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
MX348262B (es) * 2009-09-08 2017-06-05 Signature Therapeutics Inc * Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262360A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
WO2011133346A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
JP6016810B2 (ja) 2011-01-11 2016-10-26 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 酵素切断可能なオキシコドンプロドラッグを含んでなる組成物
CA2827662C (en) * 2011-03-09 2020-07-14 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) * 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176644A1 (en) * 2003-09-30 2005-08-11 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
JP2007507520A (ja) * 2003-09-30 2007-03-29 ニュー リバー ファーマシューティカルズ インコーポレイテッド 過剰摂取又は乱用を防止するための薬学組成物
WO2007120648A2 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
WO2007140272A2 (en) * 2006-05-26 2007-12-06 Pharmacofore, Inc. Controlled release of phenolic opioids
US20090137618A1 (en) * 2007-11-26 2009-05-28 Jenkins Thomas E Pro-drugs for controlled release of biologically active compounds
JP2012509846A (ja) * 2008-10-17 2012-04-26 ファーマコフォア，インク． フェノール性オピオイドの放出が減弱された医薬組成物
JP2013525348A (ja) * 2010-04-21 2013-06-20 シグネーチャー セラピューティクス，インク． 酵素切断可能なオピオイドプロドラッグとそのインヒビターとを含んでなる組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014017363; Ｂｉｏｏｒｇａｎｉｃ　Ｃｈｅｍｉｓｔｒｙ ３０, 2002, ｐ．２８５-３０１ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502972A (ja) * 2011-01-11 2014-02-06 シグネーチャー セラピューティクス，インク． 酵素切断可能なオキシコドンプロドラッグを含んでなる組成物
JP2021504351A (ja) * 2017-11-24 2021-02-15 ビョンディス・ビー．ブイ．Ｂｙｏｎｄｉｓ Ｂ．Ｖ． リンカー薬物化合物ｖｃ−ｓｅｃｏ−ＤＵＢＡ製造のための改善された方法
JP7279042B2 (ja) 2017-11-24 2023-05-22 ビョンディス・ビー．ブイ． リンカー薬物化合物ｖｃ－ｓｅｃｏ－ＤＵＢＡ製造のための改善された方法
JP2021532183A (ja) * 2018-07-27 2021-11-25 コンセントリック アナルジェジクス，インク． フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ

Also Published As

Publication number Publication date
US20120230916A1 (en) 2012-09-13
RU2012108874A (ru) 2013-09-20
AU2010293028A1 (en) 2012-04-05
IL218498A0 (en) 2012-07-31
HK1172283A1 (zh) 2013-04-19
JP2018172387A (ja) 2018-11-08
CN102695545A (zh) 2012-09-26
JP2016041698A (ja) 2016-03-31
EP2475429B1 (en) 2015-07-29
RU2600736C2 (ru) 2016-10-27
WO2011031350A1 (en) 2011-03-17
US20170119754A1 (en) 2017-05-04
CN102695545B (zh) 2016-08-17
BR112012005124A2 (pt) 2020-08-25
CA2773340A1 (en) 2011-03-17
EP2475429A1 (en) 2012-07-18
SG179026A1 (en) 2012-04-27
MX348262B (es) 2017-06-05
IL218498A (en) 2017-03-30
CA2773340C (en) 2019-07-23
US9493477B2 (en) 2016-11-15
PH12012500485A1 (en) 2012-10-22
JP6778234B2 (ja) 2020-10-28
AU2010293028B2 (en) 2014-12-18
EP2475429A4 (en) 2013-04-03
MX2012002847A (es) 2012-08-23
US10028945B2 (en) 2018-07-24
BR112012005124B1 (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
JP6778234B2 (ja) 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
JP6148182B2 (ja) 複素環式リンカーを有する活性薬剤プロドラッグ
US9095627B2 (en) Opioid prodrugs with heterocyclic linkers
DK2663187T3 (en) Compositions comprising enzyme-cleavable oxycodone prodrug
US8497237B2 (en) Compositions comprising enzyme-cleavable oxycodone prodrug
JP2013525348A (ja) 酵素切断可能なオピオイドプロドラッグとそのインヒビターとを含んでなる組成物
US9238020B2 (en) Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US20110262360A1 (en) Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
JP2015199772A (ja) 酵素切断可能なオピオイドプロドラッグとそのインヒビターとを含んでなる組成物
AU2015201341A1 (en) Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
HK1172283B (en) Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
HK1193976B (en) Active agent prodrugs with heterocyclic linkers
HK1193976A (en) Active agent prodrugs with heterocyclic linkers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150529